# PDCL3 antibody [AT8F9]

## Cat. No. GTX57608

Host	Mouse
Clonality	Monoclonal
lsotype	lgG1
Applications	WB, ICC/IF
Reactivity	Human

Package 100 μl

### Applications

#### **Application Note**

\*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
WB	Recommended starting dilution is 1:1000.
ICC/IF	Assay dependent
Not tested in other applications.	

Calculated MW


28 kDa. (<u>Note</u>)

Properties	
Form	Liquid
Buffer	PBS, 10% Glycerol
Preservative	0.02% Sodium azide
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
Concentration	1 mg/ml (Please refer to the vial label for the specific concentration.)
Immunogen	The clone AT8F9 is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with a recombinant human PDCL5 protein.
Purification	Protein A Purified
Conjugation	Unconjugated
Note	For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
	Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.




For full product information, images and publications, please visit our <u>website</u>.

### DATA IMAGES




### GTX57608 WB Image

WB analysis of various samples using GTX57608 PDCL3 antibody. Samples : Jurkat and A549 whole cell lysate Loading : 40  $\mu g$  Dilution : 1:1000



#### GTX57608 WB Image

WB analysis of Recombinant Human PDCL3 protein using GTX57608 PDCL3 antibody. Loading : 100 ng Dilution : 1:1000



#### GTX57608 ICC/IF Image

ICC/IF analysis of HeLa cells using GTX57608 PDCL3 antibody. Blue: DAPI Green: Primary antibody Dilution: 1:100



For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 05 / 13 Page 2 of 2